Surg-23. Efficacy of Laser Interstitial Thermal Therapy (litt) for Newly Diagnosed and Recurrent Idh Wild-type Glioblastoma
Year: 2022
Type: article
Abstract: Treatment options for glioblastoma remain limited, particularly for those who are not eligible for traditional resection, whether due to lesion location or inability to tolerate open craniotomy. Maximal-safe resection followed by radiation with concurrent and adjuvant temozolomide offers the best outcomes for patients. Unfortunately, not all tumors are amenable to conventional surgical resection at the time of diagnosis with only about 1/3 of patients able to receive a gross-total resection and 15-25% of patients receiving biopsy only, thus reducing their projected overall survival to 9 months. Laser interstitial thermal therapy (LITT) is a minimally invasive, cytoreductive tool, that has demonstrated safety as a surgical approach to treat primary brain tumors. METHODS Data from LAANTERN prospective multicenter registry (NCT02392078) was analyzed to determine clinical outcomes for patients with new and recurrent IDH wild-type glioblastoma (N=89). Demographics, intraprocedural data, adverse events, KPS, health-economics, and survival data were prospectively collected then analyzed separately for newly diagnosed GBM (N=29) and recurrent GBM (N=60). RESULTS Median overall-survival was 9.73 months (95% CI: 5.16, 15.91) for newly diagnosed patients and median post-procedure survival was 8.97 (6.94, 12.36) months for recurrent patients. Median overall-survival for newly diagnosed patients receiving post-LITT chemoradiotherapy was 16.14 months (6.11, not reached). The median length of hospital stay was 50 hours and 80% of patients were discharged to home. CONCLUSIONS LITT offers an effective cytoreductive approach for patients with newly diagnosed and recurrent IDH wild-type glioblastoma. Importantly, its use in newly diagnosed patients who receive post-LITT chemoradiotherapy leads to a median OS similar to that of patients treated with conventional surgical resection. LITT remains an important alternative for patients with inoperable tumors or those not amenable to resection. Enrollment in LAANTERN is ongoing and these cohorts will be revisited as data continues to mature. Benefits beyond cytoreduction are also being actively explored.
Source: Neuro-Oncology
Authors: John de Groot, Albert Kim, Sujit Prabhu, Ganesh Rao, Adrian Laxton, Peter Fecci, Barbara O'Brien, Andrew Sloan, Veronica Chiang, Stephen Tatter, Alireza Mohammadi, Dimitris Placantonakis, Roy Strowd, Clark Chen, Constantinos Hadjipanayis, Mustafa Khasraw, David Sun, David Piccioni, Kaylyn Sinicrope, Jian Campian, Sylvia Kurz, Brian Williams, Kris Smith, Zulma Tovar-Spinoza, Eric Leuthardt
Institutions: University of California, San Francisco, Washington University in St. Louis, The University of Texas MD Anderson Cancer Center, Baylor College of Medicine, Atrium Health Wake Forest Baptist, Duke Medical Center, University Hospitals Cleveland Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Yale University, Cleveland Clinic, New York University, Wake Forest Baptist Comprehensive Cancer Center, University of Minnesota, Icahn School of Medicine at Mount Sinai, Norton Healthcare, UC San Diego Health System, University of California San Diego, Mayo Clinic, Mayo Clinic Comprehensive Cancer Center (Minnesota), NYU Langone’s Laura and Isaac Perlmutter Cancer Center, University of Louisville, Barrow Neurological Institute, SUNY Upstate Medical University
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4309018284